Simultaneous recordings of gastric manometry and myoelectrical activity were made in 10 patients with gastroparesis. Intravenous erythromycin (100 mg) was administered in the fasting state for a ...period of 30 min. Subcutaneous injection of octreotide (100 microg) was administered before one of the four identical test meals. It was found that octreotide significantly decreased the antral motility index (30-min fasting: 4.51+/-1.04 vs 1.75+/-0.97, P < 0.02; 60-min fed: 5.16+/-1.44 vs 3.4+/-1.41, P < 0.05) and the dominant power of the EGG (fasting power: 35.19+/-1.54 vs 30.84+/-1.57 dB, P < 0.004; postprandial power increase: 5.52+/-1.06 vs -0.27+/-0.87, P < 0.001). Erythromycin significantly increased the antral motility index (3.16+/-0.96 vs 9.5+/-0.61, P < 0.001) and the dominant power of the EGG (28.86+/-1.57 dB vs 33.55+/-1.59 dB, P < 0.005) in the fasting state. An improvement in the regularity of the gastric slow wave was also noted with erythromycin. It was concluded that: (1) the inhibitory effect of octreotide on postprandial gastric motility and myoelectrical activity suggests that caution should be exercised when octreotide is used in patients with gastroparesis; and (2) the stimulatory effect of erythromycin on gastric myoelectrical activity may enhance gastric motility and gastric emptying in patients with gastroparesis.
We provide the most precise measurement of the WW production cross section in pp collisions to date at a center of mass energy of 1.96 TeV, and set limits on the associated trilinear gauge couplings. ...The WW -> l nu l(')nu (l, l(')=e, mu) decay channels are analyzed in 1 fb(-1) of data collected by the D0 detector at the Fermilab Tevatron Collider. The measured cross section is sigma(pp -> WW)=11.5 +/- 2.1(stat+syst)+/- 0.7(lumi) pb. One- and two-dimensional 95% C.L. limits on trilinear gauge couplings are provided.
We present a measurement of the top quark pair (t (t) over bar) production cross section (sigma(t (t) over bar)) in pp collisions at root s = 1.96 TeV using 230 pb(-1) of data collected by the DO ...experiment at the Fermilab Tevatron Collider. We select events with one charged lepton (electron or muon), missing transverse energy, and jets in the final state. We employ lifetime-based b-jet identification techniques to further enhance the t F purity of the selected sample. For a top quark mass of 175 GeV, we measure sigma(t (t) over bar) 8.6(-1.5)(+1.6) (stat. + syst.) +/- 0.6(lumi.) pb, in agreement with the standard model expectation.
A small molecule factor VIIa inhibitor has recently been reported by the Ono Pharmaceutical Company. Herein, we outline an efficient and convergent, synthetic route that relies upon a ...palladium-catalyzed Stille coupling reaction as a key step for the synthesis of the inhibitor.
We report a new measurement of the pseudorapidity (eta) and transverse-energy ( E(T)) dependence of the inclusive jet production cross section in pp(macro) collisions at square root of s = 1.8 TeV ...using 95 pb(-1) of data collected with the D0 detector at the Fermilab Tevatron. The differential cross section d(2)sigma/(dE(T)d eta) is presented up to eta = 3, significantly extending previous measurements. The results are in good overall agreement with next-to-leading order predictions from QCD and indicate a preference for certain parton distribution functions.
We present a measurement of the direct CP-violating charge asymmetry in B-+/- mesons decaying to J/psi K-+/- and J/psi pi(+/-) where J/psi decays to mu(+)mu(-), using the full run II data set of 10.4 ...fb(-1) of proton-antiproton collisions collected using the D0 detector at the Fermilab Tevatron Collider. A difference in the yield of B- and B+ mesons in these decays is found by fitting to the difference between their reconstructed invariant mass distributions resulting in asymmetries of A(J/psi K) = 0.59 +/- 0.37%, which is the most precise measurement to date, and A(J/psi pi) = -4.2 +/- 4.5%. Both measurements are consistent with standard model predictions.
A novel series of pyrrolidine‐1,2‐dicarboxamides was discovered as factor Xa inhibitors using structure‐based drug design. This series consisted of a neutral 4‐chlorophenylurea P1, a ...biphenylsulfonamide P4 and a d‐proline scaffold (1, IC50 = 18 nm). Optimization of the initial hit resulted in an orally bioavailable, subnanomolar inhibitor of factor Xa (13, IC50 = 0.38 nm), which was shown to be efficacious in a canine electrolytic model of thrombosis with minimal bleeding.
We present the first combined measurement of the rapidity and transverse momentum dependence of dijet azimuthal decorrelations, using the recently proposed quantity R-Delta phi. The variable R-Delta ...phi measures the fraction of the inclusive dijet events in which the azimuthal separation of the two jets with the highest transverse momenta is less than a specified value of the parameter Delta phi(max). The quantity R-Delta phi is measured in p (p) over bar collisions at root s = 1.96 TeV, as a function of the dijet rapidity interval, the total scalar transverse momentum, and Delta phi(max). The measurement uses an event sample corresponding to an integrated luminosity of 0.7 fb(-1) collected with the DO detector at the Fermilab Tevatron Collider. The results are compared to predictions of a perturbative QCD calculation at next-to-leading order in the strong coupling with corrections for non-perturbative effects. The theory predictions describe the data well, except in the kinematic region of large dijet rapidity intervals and small Delta phi(max).
Even when large doses of heparin are administered during cardiopulmonary bypass, thrombin is produced. Thrombin is a powerful protease that is associated with the thrombotic and bleeding ...complications of open heart surgery and is produced by cleavage of prothrombin by factor Xa. This study assessed the ability of a specific inhibitor of factor Xa, recombinant tick anticoagulant peptide (rTAP), alone or in combination with standard heparin and a low-molecular-weight heparin, enoxaparin, to suppress thrombin formation and activity during in vitro extracorporeal circulation.
Fresh, anticoagulated human blood was recirculated for 2 hours in an extracorporeal membrane oxygenator perfusion circuit at 37 degrees C. Four anticoagulant protocols were evaluated; porcine heparin (3.75 U/mL); enoxaparin (17.5 U/mL); rTAP (4 mumol/L); and porcine heparin plus rTAP (2 mumol/L). Blood samples were obtained for analysis from the donor, after anticoagulation, and after 5, 30, 60, and 120 minutes of recirculation. There were no significant differences between groups in platelet count, response to adenosine diphosphate, or prothrombin fragment (F1.2) production. rTAP plus heparin reduced beta-thromboglobulin release; fibrinopeptide A concentrations were significantly higher with rTAP alone. Enoxaparin strongly and significantly inhibited complement C5b9 production and neutrophil elastase release and was associated with significantly increased concentrations of C1-C1 inhibitor and kallikrein-C1 inhibitor complexes.
rTAP does not reduce thrombin formation or activity during in vitro extracorporeal circulation. Enoxaparin markedly inhibits formation of the complement membrane attack complex and neutrophil elastase release, possibly by accelerating C1 inhibitor activity.
PDF
